中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 6
Jun.  2018
Turn off MathJax
Article Contents

Diagnosis and treatment of drug-induced liver injury

DOI: 10.3969/j.issn.1001-5256.2018.06.004
  • Received Date: 2018-04-10
  • Published Date: 2018-06-20
  • Due to a lack of specific biomarkers, the diagnosis of drug-induced liver injury (DILI) mainly depends on the method of exclusion. The Roussel Uclaf Causality Assessment Method (RUCAM) scale is the most widely used causality assessment scale and is relatively objective, but it is still waiting for further improvement. Another method is global introspection or expert opinion, which is relatively subjective, and the simplified global introspection method is commonly used in clinical practice. The Structured Expert Opinion Procedure (SEOP) created by the US DILI network (DILIN) is very complicated and time-consuming and thus cannot be used in clinical practice. The drug rechallenge test (DRT) with a positive result is considered the gold standard for the diagnosis of DILI, but DILI cannot be excluded based on the negative result of DRT. The value of lymphocyte transformation test (LTT) , modified LTT, monocyte-derived hepatocyte-like cell lactate-dehydrogenase release test, and various predictive models for drug hepatotoxicity in the diagnosis of DILI awaits further assessment.The differential diagnosis of autoimmune-mediated DILI and traditional autoimmune liver diseases usually depends on liver biopsy, the type and titer of autoantibody, and response to glucocorticoids. Reasonable timing of drug withdrawal and application of anti-inflammatory liver-protecting drugs may help most DILI patients recover. Generally, the prophylactic use of anti-inflammatory liver-protecting drugs is not recommended, except in special situations. In-depth studies are needed for the precise diagnosis and prevention/treatment of DILI.

     

  • loading
  • [1]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
    [2]YU YC, MAO YM, CHEN CW, et al.CSH guideline for the diagnosis and treatment of drug-induced liver injury[J].Hepatol Int, 2017, 11 (3) :221-241.
    [3]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.
    [4]ROCKEY DC, SEEFF LB, ROCHON J, et al.US drug-induced liver injury network.Causality assessment in drug-induced liver injury using a structured expert opinion process:Comparison to the Roussel-Uclaf causality assessment method[J].Hepatology, 2010, 51 (6) :2117-2126.
    [5]DANAN G, TESCHKE R.Drug-induced liver injury:Why is the roussel uclaf causality assessment method (RUCAM) still used 25years after its launch?[J].Drug Saf, 2018.[Epub ahead of print].
    [6]DANAN G, BNICHOU C.Causality assessment of adverse reactions to drugs—I.A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46 (11) :1323-1330.
    [7]DANAN G, TESCHKE R.RUCAM in drug and herb induced liver injury:The update[J].Int J Mol Sci, 2015, 17 (1) .pii:E14.
    [8]YU YC, CHEN CW.A new version of the Roussel Uclaf Causality Assessment Method:An important assessment tool for drug and herb-induced liver injury[J].Chin Hepatol, 2016, 21 (6) :493-500. (in Chinese) 于乐成, 陈成伟.新版RUCAM:药物和草药诱导性肝损伤的重要评估工具[J].肝脏, 2016, 21 (6) :493-500.
    [9]YU YC, MAO YM, CHEN CW.A new version of the Roussel Uclaf Causality Assessment Method scale:evaluation and several opinions[J].Chin Hepatol, 2016, 21 (6) :432-433. (in Chinese) 于乐成, 茅益民, 陈成伟.对新版RUCAM量表的评价和几点商榷意见[J].肝脏, 2016, 21 (6) :432-433.
    [10]HOU JX, PU F, YU YC.Drug rechallenge test for drug-induced liver injury[J].Chin Hepatol, 2017, 22 (11) :978-982. (in Chinese) 侯俊兴, 卜凡, 于乐成.药物性肝损伤的药物再刺激试验[J].肝脏, 2017, 22 (11) :978-982.
    [11]YU YC, FAN Y, CHEN CW.Rechallenge test for drug-induced liver injury:issues on intentional rechallenge, operation, and judgment[J].Chin Hepatol, 2017, 22 (12) :1073-1076. (in Chinese) 于乐成, 范晔, 陈成伟.药物性肝损伤再刺激试验:能否故意?如何操作?如何判断[J].肝脏, 2017, 22 (12) :1073-1076.
    [12]YU YC, HE CL, HOU JL.Biomarkers in drug-induced liver injuries[J].J Pract Hepatol, 2014, 17 (6) :564-568. (in Chinese) 于乐成, 何长伦, 侯金林.药物诱导性肝损伤生物标志物研究进展[J].实用肝脏病杂志, 2014, 17 (6) :564-568.
    [13]WATANABE M, SHIBUYA A.Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales[J].Hepatol Res, 2004, 30 (3) :148-154.
    [14]WHRITENOUR J, KO M, ZONG Q, et al.Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response[J].J Immunotoxicol, 2017, 14 (1) :31-38.
    [15]BENESIC A, LEITL A, GERBES AL.Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury[J].Gut, 2016, 65 (9) :1555-1563.
    [16]CHEN M, BORLAK J, TONG W.A model to predict severity of drug-induced liver injury in humans[J].Hepatology, 2016, 64 (3) :931-940.
    [17]PROCTOR WR, FOSTER AJ, VOGT J, et al.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury[J].Arch Toxicol, 2017, 91 (8) :2849-2863.
    [18]VORRINK S, ZHOU Y, INGELMAN-SUNDBERG M, et al.Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions[J].Toxicol Sci, 2018.[Epub ahead of print].
    [19]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1637.
    [20]FORD R, SCHWARTZ L, DANCEY J, et al.US Food and Drug Administration.Center for Drug Evaluation and Research (CDER) , Center for Biologics Evaluation and Research (CBER) .Guidance for industry:Drug-induced liver injury—premarketing clinical evaluation[J].Eur J Cancer, 2009, 45 (2) :268-274.
    [21] Liver Failure and Artificial Liver Group, Chinese Severe Liver Diseases and Artificial Liver Group.Diagnostic and treatment guidelines for liver failure (2012 version) [J].Chin J Hepatol, 2013, 21 (3) :177-183. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝痛与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华肝脏病杂志, 2013, 21 (3) :177-183.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2900) PDF downloads(656) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return